BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Qi W, Niu J, Qin Q, Qiao Z, Gu Y. Astragaloside IV attenuates glycated albumin-induced epithelial-to-mesenchymal transition by inhibiting oxidative stress in renal proximal tubular cells. Cell Stress Chaperones 2014;19:105-14. [PMID: 23719694 DOI: 10.1007/s12192-013-0438-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Nie Y, Li S, Yi Y, Su W, Chai X, Jia D, Wang Q. Effects of astragalus injection on the TGFβ/Smad pathway in the kidney in type 2 diabetic mice. BMC Complement Altern Med 2014;14:148. [PMID: 24885228 DOI: 10.1186/1472-6882-14-148] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
2 Wu Y, Xiao W, Pei C, Wang M, Wang X, Huang D, Wang F, Wang Z. Astragaloside IV alleviates PM2.5-induced lung injury in rats by modulating TLR4/MyD88/NF-κB signalling pathway. Int Immunopharmacol 2021;91:107290. [PMID: 33383446 DOI: 10.1016/j.intimp.2020.107290] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
3 Qi W, Niu J, Qin Q, Qiao Z, Gu Y. Glycated albumin triggers fibrosis and apoptosis via an NADPH oxidase/Nox4-MAPK pathway-dependent mechanism in renal proximal tubular cells. Mol Cell Endocrinol 2015;405:74-83. [PMID: 25681565 DOI: 10.1016/j.mce.2015.02.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
4 Murata I, Abe Y, Yaginuma Y, Yodo K, Kamakari Y, Miyazaki Y, Baba D, Shinoda Y, Iwasaki T, Takahashi K, Kobayashi J, Inoue Y, Kanamoto I. Astragaloside-IV prevents acute kidney injury and inflammation by normalizing muscular mitochondrial function associated with a nitric oxide protective mechanism in crush syndrome rats. Ann Intensive Care 2017;7:90. [PMID: 28871521 DOI: 10.1186/s13613-017-0313-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
5 Zhong Y, Menon MC, Deng Y, Chen Y, He JC. Recent Advances in Traditional Chinese Medicine for Kidney Disease. Am J Kidney Dis 2015;66:513-22. [PMID: 26015275 DOI: 10.1053/j.ajkd.2015.04.013] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 8.3] [Reference Citation Analysis]
6 Du Q, Deng R, Gao C, Shen J. Combination of matrix solid phase dispersion and response surface evaluation for simultaneous detections of multiple bioactive constituents of traditional Chinese medicine formula: Using Baoyuan Capsule as an example. Journal of Pharmaceutical and Biomedical Analysis 2020;190:113495. [DOI: 10.1016/j.jpba.2020.113495] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Wang Y, Jiang F, Cheng H, Tan X, Liu Y, Wei C, Song E. Astragaloside IV Protects Against Oxidative Stress in Calf Small Intestine Epithelial Cells via NFE2L2-Antioxidant Response Element Signaling. Int J Mol Sci 2019;20:E6131. [PMID: 31817362 DOI: 10.3390/ijms20246131] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Huang Y, Jin H, Chen J, Jiang X, Li P, Ren Y, Liu W, Yao J, Folger JK, Smith GW, Lv L. Effect of Vitamin D on basal and Luteinizing Hormone (LH) induced testosterone production and mitochondrial dehydrogenase activity in cultured Leydig cells from immature and mature rams. Animal Reproduction Science 2015;158:109-14. [DOI: 10.1016/j.anireprosci.2015.05.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
9 Zhang J, Wu C, Gao L, Du G, Qin X. Astragaloside IV derived from Astragalus membranaceus: A research review on the pharmacological effects. Adv Pharmacol 2020;87:89-112. [PMID: 32089240 DOI: 10.1016/bs.apha.2019.08.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
10 Song G, Han P, Sun H, Shao M, Yu X, Wang W, Wang D, Yi W, Ge N, Li S, Yi T. Astragaloside IV ameliorates early diabetic nephropathy by inhibition of MEK1/2-ERK1/2-RSK2 signaling in streptozotocin-induced diabetic mice. J Int Med Res 2018;46:2883-97. [PMID: 29896981 DOI: 10.1177/0300060518778711] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
11 Qin S, Yin J, Huang S, Lin J, Fang Z, Zhou Y, Huang K. Astragaloside IV Protects Ethanol-Induced Gastric Mucosal Injury by Preventing Mitochondrial Oxidative Stress and the Activation of Mitochondrial Pathway Apoptosis in Rats. Front Pharmacol 2019;10:894. [PMID: 31474858 DOI: 10.3389/fphar.2019.00894] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
12 Xu F, Cui WQ, Wei Y, Cui J, Qiu J, Hu LL, Gong WY, Dong JC, Liu BJ. Astragaloside IV inhibits lung cancer progression and metastasis by modulating macrophage polarization through AMPK signaling. J Exp Clin Cancer Res 2018;37:207. [PMID: 30157903 DOI: 10.1186/s13046-018-0878-0] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 11.0] [Reference Citation Analysis]
13 Zhang, Yang L, Shergis J, Zhang L, Zhang AL, Guo X, Qin X, Johnson D, Liu X, Lu C, Xue CC, Mao W. Chinese herbal medicine for diabetic kidney disease: a systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open 2019;9:e025653. [PMID: 31048437 DOI: 10.1136/bmjopen-2018-025653] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
14 Li L, Hou X, Xu R, Liu C, Tu M. Research review on the pharmacological effects of astragaloside IV. Fundam Clin Pharmacol 2017;31:17-36. [PMID: 27567103 DOI: 10.1111/fcp.12232] [Cited by in Crossref: 113] [Cited by in F6Publishing: 118] [Article Influence: 18.8] [Reference Citation Analysis]
15 Kim MH, Kim SH, Yang WM. Beneficial effects of Astragaloside IV for hair loss via inhibition of Fas/Fas L-mediated apoptotic signaling. PLoS One 2014;9:e92984. [PMID: 24676213 DOI: 10.1371/journal.pone.0092984] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
16 Li N, Wang X, Wang P, Fan H, Hou S, Gong Y. Emerging medical therapies in crush syndrome - progress report from basic sciences and potential future avenues. Ren Fail 2020;42:656-66. [PMID: 32662306 DOI: 10.1080/0886022X.2020.1792928] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Wang X, Gao Y, Tian N, Wang T, Shi Y, Xu J, Wu B. Astragaloside IV inhibits glucose-induced epithelial-mesenchymal transition of podocytes through autophagy enhancement via the SIRT-NF-κB p65 axis. Sci Rep 2019;9:323. [PMID: 30674969 DOI: 10.1038/s41598-018-36911-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 9.7] [Reference Citation Analysis]
18 He P, Li Z, Yue Z, Gao H, Feng G, Wang P, Huang Y, Luo W, Hong H, Liang L, Chen S, Liu P. SIRT3 prevents angiotensin II-induced renal tubular epithelial-mesenchymal transition by ameliorating oxidative stress and mitochondrial dysfunction. Molecular and Cellular Endocrinology 2018;460:1-13. [DOI: 10.1016/j.mce.2017.04.027] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
19 Wang X, Gao Y, Tian N, Zou D, Shi Y, Zhang N. Astragaloside IV improves renal function and fibrosis via inhibition of miR-21-induced podocyte dedifferentiation and mesangial cell activation in diabetic mice. Drug Des Devel Ther 2018;12:2431-42. [PMID: 30122901 DOI: 10.2147/DDDT.S170840] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
20 Shao A, Guo S, Tu S, Ammar AB, Tang J, Hong Y, Wu H, Zhang J. Astragaloside IV alleviates early brain injury following experimental subarachnoid hemorrhage in rats. Int J Med Sci 2014;11:1073-81. [PMID: 25136262 DOI: 10.7150/ijms.9282] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
21 Huang H, Lai S, Wan Q, Qi W, Liu J. Astragaloside IV protects cardiomyocytes from anoxia/reoxygenation injury by upregulating the expression of Hes1 protein. Can J Physiol Pharmacol 2016;94:542-53. [PMID: 27070866 DOI: 10.1139/cjpp-2015-0457] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
22 Sutariya B, Taneja N, Badgujar L, Saraf M. Modulatory effect of betanin on high glucose induced epithelial to mesenchymal transition in renal proximal tubular cells. Biomed Pharmacother 2017;89:18-28. [PMID: 28214684 DOI: 10.1016/j.biopha.2017.02.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
23 Jiang X, Cao X, Huang Y, Chen J, Yao X, Zhao M, Liu Y, Meng J, Li P, Li Z, Yao J, Smith GW, Lv L. Effects of treatment with Astragalus Membranaceus on function of rat leydig cells. BMC Complement Altern Med 2015;15:261. [PMID: 26231491 DOI: 10.1186/s12906-015-0776-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
24 Sun R, Ren H, Wei J. Effects of astrogaloside on the inflammation and immunity of renal failure patients receiving maintenance dialysis. Exp Ther Med 2018;15:2307-12. [PMID: 29456637 DOI: 10.3892/etm.2018.5709] [Reference Citation Analysis]
25 Wang YN, Zhao SL, Su YY, Feng JX, Wang S, Liao XM, Wang LN, Li JC, Meng P, Li HY, Zhang YF. Astragaloside IV attenuates high glucose-induced EMT by inhibiting the TGF-β/Smad pathway in renal proximal tubular epithelial cells. Biosci Rep 2020;40:BSR20190987. [PMID: 32515466 DOI: 10.1042/BSR20190987] [Reference Citation Analysis]
26 Zhai R, Jian G, Chen T, Xie L, Xue R, Gao C, Wang N, Xu Y, Gui D. Astragalus membranaceus and Panax notoginseng, the Novel Renoprotective Compound, Synergistically Protect against Podocyte Injury in Streptozotocin-Induced Diabetic Rats. J Diabetes Res 2019;2019:1602892. [PMID: 31179338 DOI: 10.1155/2019/1602892] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
27 Lu Y, Li S, Wu H, Bian Z, Xu J, Gu C, Chen X, Yang D. Beneficial effects of astragaloside IV against angiotensin II-induced mitochondrial dysfunction in rat vascular smooth muscle cells. Int J Mol Med 2015;36:1223-32. [PMID: 26398547 DOI: 10.3892/ijmm.2015.2345] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
28 Xu W, Shao X, Tian L, Gu L, Zhang M, Wang Q, Wu B, Wang L, Yao J, Xu X, Mou S, Ni Z. Astragaloside IV ameliorates renal fibrosis via the inhibition of mitogen-activated protein kinases and antiapoptosis in vivo and in vitro. J Pharmacol Exp Ther 2014;350:552-62. [PMID: 24951279 DOI: 10.1124/jpet.114.214205] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 5.3] [Reference Citation Analysis]
29 Liu ZH, Liu HB, Wang J. Astragaloside IV protects against the pathological cardiac hypertrophy in mice. Biomed Pharmacother 2018;97:1468-78. [PMID: 29793309 DOI: 10.1016/j.biopha.2017.09.092] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]